You have 9 free searches left this month | for more free features.

High-Risk MDS

Showing 26 - 50 of >10,000

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Leukemia, Myeloid, Acute, MDS, Myelodysplastic Syndrome Acute Myeloid Leukemia Trial in Denver (Nivolumab)

Withdrawn
  • Leukemia, Myeloid, Acute
  • +2 more
  • Denver, Colorado
    Colorado Blood Cancer Institute
Apr 20, 2021

MDS Trial in Bronx (Pyrimethamine)

Withdrawn
  • Myelodysplastic Syndromes
  • Bronx, New York
    Montefiore Medical Center
Sep 15, 2021

Leukemia, Myeloid, Acute Trial (GSK3745417)

Not yet recruiting
  • Leukemia, Myeloid, Acute
  • (no location specified)
Jun 15, 2022

Acute Myeloid Leukemia, Blasts 20 Percent or More of Bone Marrow Nucleated Cells, High Risk Myelodysplastic Syndrome Trial in

Recruiting
  • Acute Myeloid Leukemia
  • +7 more
  • Houston, Texas
    M D Anderson Cancer Center
Dec 7, 2022

Acute Myelogenous Leukemia, Myelodysplastic Syndrome Trial in Valhalla (Gemtuzumab Ozogamicin)

Active, not recruiting
  • Acute Myelogenous Leukemia
  • Myelodysplastic Syndrome
  • Gemtuzumab Ozogamicin
  • Valhalla, New York
    New York Medical College
Nov 11, 2021

High Risk Myelodysplastic Syndrome Trial in Houston (Guadecitabine)

Active, not recruiting
  • High Risk Myelodysplastic Syndrome
  • Houston, Texas
    M D Anderson Cancer Center
Feb 2, 2022

MDS (MDS), Acute Myelogenous Leukemia (AML) Trial in United States (low dose 5'-azacitidine)

Active, not recruiting
  • Myelodysplastic Syndromes (MDS)
  • Acute Myelogenous Leukemia (AML)
  • low dose 5'-azacitidine
  • Basking Ridge, New Jersey
  • +6 more
Dec 1, 2022

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, High Risk

Recruiting
  • Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
  • +5 more
  • Gemtuzumab Ozogamicin
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Sep 22, 2022

High Risk Myelodysplastic Syndrome, IPSS Risk Category Intermediate-1, Myelodysplastic Syndrome Trial in Houston (Azacitidine,

Active, not recruiting
  • High Risk Myelodysplastic Syndrome
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Aug 11, 2022

Acute Myeloid Leukaemia (AML), MDS (MDS) Trial in Germany, Netherlands (Panobinostat)

Active, not recruiting
  • Acute Myeloid Leukaemia (AML)
  • Myelodysplastic Syndromes (MDS)
  • Stuttgart, Baden-Württemberg, Germany
  • +18 more
Dec 13, 2021

MDS, Progressive Disease Trial in Buffalo, Winston-Salem (CPI-613, Hydroxychloroquine)

Withdrawn
  • Myelodysplastic Syndromes
  • Progressive Disease
  • Buffalo, New York
  • +1 more
Apr 8, 2021

AML/MDS Trial in Worldwide (Decitabine, Midostaurin)

Active, not recruiting
  • AML/MDS
  • Antwerpen, Belgium
  • +36 more
Dec 29, 2021

Acute Myeloid Leukemia, de Novo Myelodysplastic Syndrome, Myelodysplastic Syndrome Trial in Chicago (Laboratory Biomarker

Completed
  • Acute Myeloid Leukemia
  • +4 more
  • Chicago, Illinois
    University of Chicago Comprehensive Cancer Center
May 12, 2021

Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome Trial in Houston (Nivolumab, Idarubicin, Cytarabine)

Completed
  • Leukemia
  • +2 more
  • Houston, Texas
    University of Texas MD Anderson Cancer Center
Sep 9, 2021

Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome Trial in Houston (Decitabine and Cedazuridine, Venetoclax)

Recruiting
  • Chronic Myelomonocytic Leukemia
  • Myelodysplastic Syndrome
  • Houston, Texas
    M D Anderson Cancer Center
Jul 18, 2022

Acute Lymphocytic Leukaemia; Acute Myeloid Leukaemia Refractory; Myelodysplastic Syndrome Trial in Australia, Netherlands,

Recruiting
  • Acute Lymphocytic Leukaemia; Acute Myeloid Leukaemia Refractory; Myelodysplastic Syndrome
  • Duarte, California
  • +12 more
Jan 4, 2023

Recurrent Chronic Myelomonocytic Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Chronic Myelomonocytic Leukemia Trial

Recruiting
  • Recurrent Chronic Myelomonocytic Leukemia
  • +4 more
  • Houston, Texas
    M D Anderson Cancer Center
Jul 21, 2022

Relapsed Acute Myeloid Leukemia (AML), Refractory Acute Myeloid Leukemia (AML), High-risk Myelodysplastic Syndrome (MDS) Trial

Completed
  • Relapsed Acute Myeloid Leukemia (AML)
  • +2 more
  • Atlanta, Georgia
  • +5 more
Apr 4, 2022

Acute Myelogenous Leukemia in Relapse, Acute Myelogenous Leukemia, Relapsed, Adult, Acute Myelogenous Leukemia, Adult Trial in

Terminated
  • Acute Myelogenous Leukemia in Relapse
  • +4 more
  • Tucson, Arizona
  • +12 more
Aug 18, 2022

Acute Myelogenous Leukemia AML, Myelodysplastic Syndrome MDS Trial in Maywood (Vidaza and Valproic Acid)

Recruiting
  • Acute Myelogenous Leukemia AML
  • Myelodysplastic Syndrome MDS
  • Vidaza and Valproic Acid
  • Maywood, Illinois
    Loyola University Cardinal Bernardin Cancer Center
Apr 23, 2021

AML and High Risk MDS Trial in Worldwide (LGH447, LGH447 + midostaurin)

Completed
  • AML and High Risk MDS
  • Ann Arbor, Michigan
  • +8 more
Dec 16, 2020

Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in Newcastle (Bisantrene DiHCl

Recruiting
  • Acute Myeloid Leukemia
  • +4 more
  • Bisantrene Dihydrochloride (high dose)
  • +3 more
  • Newcastle, New South Wales, Australia
    Calvary Mater
Jul 14, 2022

Myelodysplasia, Leukemia Trial in Providence (chemo)

Terminated
  • Myelodysplasia
  • Leukemia
  • Providence, Rhode Island
    Lifespan Hospitals
Jan 5, 2022